Bioxytran, Inc. BIXT
0.02 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.0201 Day range 0.0202
0.02 52-week range 0.0949
- YTD
- -69.53%
- 1 year
- -65.39%
News
globenewswire.com Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets Non-systemic, pre-meal chewable nutraceutical designed to help blunt post-meal blood sugar spikes enters a region where roughly 7.5 million adults in the UAE, Saudi Arabia and Kuwait are living with…
globenewswire.com Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar Finished inventory of both products has been manufactured; Company is finalizing go-to-market plans Boston, MA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) ("Bioxytran" or the…
globenewswire.com Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04,…
globenewswire.com Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research Report discusses ProLectin-M Phase 2 clinical results, planned 408-patient registrational trial, the BXT-25 oxygen-therapeutic platform, and Bioxytran's A-SUQAR commercial distribution agreement…
globenewswire.com Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25 Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company…
defenseworld.net Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a…
globenewswire.com BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology…
globenewswire.com Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran,…
accessnewswire.com Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a…
globenewswire.com Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled,…
defenseworld.net Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update Bioxytran, Inc. (OTCMKTS:BIXT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 5,695 shares, an increase of 1,798.3% from…
defenseworld.net Bioxytran Conference: CEO touts broad-spectrum antiviral strategy, cites strong COVID Phase II results Bioxytran (OTCMKTS:BIXT) CEO David Platt outlined the company's focus on developing drugs based on polysaccharides-complex carbohydrates-across three areas: antiviral treatment, early-stage stroke…
globenewswire.com Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning…
defenseworld.net Bioxytran (OTCMKTS:BIXT) vs. Structure Therapeutics (NASDAQ:GPCR) Head-To-Head Survey Bioxytran (OTCMKTS:BIXT - Get Free Report) and Structure Therapeutics (NASDAQ: GPCR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies…
globenewswire.com Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025.…
globenewswire.com Bioxytran Announces Initiation of Coverage of its Stock by Independent Research BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer's, and…
globenewswire.com Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is…
globenewswire.com Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is…
globenewswire.com Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment - ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Tuesday